Stay updated on Long Term Extension of Risankizumab in Crohn's Disease Clinical Trial
Sign up to get notified when there's something new on the Long Term Extension of Risankizumab in Crohn's Disease Clinical Trial page.

Latest updates to the Long Term Extension of Risankizumab in Crohn's Disease Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check17 days agoChange DetectedThe webpage has been updated to include new details about the study on Crohn's disease, specifically regarding the treatment protocol with risankizumab, and the involvement of Boehringer Ingelheim as a collaborator. Additionally, the revision number has been updated to v2.15.0.SummaryDifference16%
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check75 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check89 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
Stay in the know with updates to Long Term Extension of Risankizumab in Crohn's Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long Term Extension of Risankizumab in Crohn's Disease Clinical Trial page.